Arbutus Biopharma Stock News

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Arbutus Biopharma (ABUS) announces its 2022 corporate objectives and provided a financial update

WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commerciali

Arbutus Biopharma Corporation (NASDAQ:ABUS) with the stream of 0.00% also noticed, India Banco Santander, S.A. (NYSE:SAN) encountered a rapid change of 2.84% in the last hour of Thursdays trading session. The post Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) appeared first on Stocks Equity .

Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research []

The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,

ROIV has moved up 88% in December in reaction to a patent dispute between Moderna and Arbutus falling in favor of Arbutus. The patent is licensed to a private company called Genevant. ROIV owns an eff

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company with research specialization in chronic hepatitis B virus (HBV). In December 2021, ABUS reported its victory in the patent d

Equities analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to announce earnings of ($0.18) per share for the current quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of ($0.23) in []

Equities research analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to report sales of $3.39 million for the current quarter, Zacks reports. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest sales estimate coming in at $3.47 million and the lowest estimate coming in at $3.30 million. Arbutus Biopharma posted sales of $2.39 million []

MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a SAVE-1 (Sustained Anti-Viral Efficacy) clinical trial will evaluate a triple combination of Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, and tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor.

5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News

Brokerages expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post $3.39 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Arbutus Biopharma’s earnings. The highest sales estimate is $3.47 million and the lowest is $3.30 million. Arbutus Biopharma reported sales of $2.39 million in the same quarter last year, […]

In the last trading session, 7.06 million shares of the Arbutus Biopharma Corporation (NASDAQ:ABUS) were traded, and its beta was 2.60. Most recently the company’s share price was $4.14, and it changed around -$0.17 or -3.94% from the last close, which brings the market valuation of the company to $581.59M. ABUS currently trades at a … Arbutus Biopharma Corporation (NASDAQ: ABUS): Would You Buy Today? Read More »

(RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. As per the agreement, Arbutus would receive a $40 million upfront payment and